Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low‐dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant‐ineligible patients with newly diagnosed...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Haematol
Glavni autori: Lu, Jin, Lee, Jae H., Huang, Shang‐Yi, Qiu, Lugui, Lee, Je‐Jung, Liu, Ting, Yoon, Sung‐Soo, Kim, Kihyun, Shen, Zhi X., Eom, Hyeon S., Chen, Wen M., Min, Chang K., Kim, Hyo J., Lee, Jeong O., Kwak, Jae Y., Yiu, Wai, Chen, Guang, Ervin‐Haynes, Annette, Hulin, Cyrille, Facon, Thierry
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Haematological Malignancy
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5324608/
https://ncbi.nlm.nih.gov/pubmed/28106903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14465
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items